ArticleImmunology2012
Haem oxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus.
Article in Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Trial
- Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus.Antioxidants (Basel, Switzerland) · 2026Article
- Immunopathogenesis and Therapeutics of Systemic Lupus Erythematosus: an Integrative Review.Clinical reviews in allergy & immunology · 2025Review
- Article
- Trained Immunity Contribution to Autoimmune and Inflammatory Disorders.Frontiers in immunology · 2022Review
- Contribution of Dysregulated DNA Methylation to Autoimmunity.International journal of molecular sciences · 2021Review
- The role of heme oxygenase-1 in hematopoietic system and its microenvironment.Cellular and molecular life sciences : CMLS · 2021Review
- Immunomodulatory Effects of Heme Oxygenase-1 in Kidney Disease.Frontiers in medicine · 2021Review
- Naturally Derived Heme-Oxygenase 1 Inducers and Their Therapeutic Application to Immune-Mediated Diseases.Frontiers in immunology · 2020Review
- Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.Immunology · 2019Article
- Heme Catabolic Pathway in Inflammation and Immune Disorders.Frontiers in pharmacology · 2019Review
- Innate Immune Cells' Contribution to Systemic Lupus Erythematosus.Frontiers in immunology · 2019Review
- Heme-Oxygenase-1 Is Decreased in Circulating Monocytes and Is Associated With Impaired Phagocytosis and ROS Production in Lupus Nephritis.Frontiers in immunology · 2019Article
- Implications of macrophage polarization in autoimmunity.Immunology · 2018Review
- Heme Oxygenase-1 as a Modulator of Intestinal Inflammation Development and Progression.Frontiers in immunology · 2018Review
- Review
- Modulation of antigen processing by haem-oxygenase 1. Implications on inflammation and tolerance.Immunology · 2016Review
- Heme Oxygenase-1 in Kidney Health and Disease.Antioxidants & redox signaling · 2016Review
- Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus.Immunology · 2015Review
- Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus.Clinical and experimental immunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple functional alterations affecting immune cells, such as B cells, T cells, dendritic cells (DCs) and monocytes. During SLE, the immunogenicity of monocytes and DCs is significantly up-regulated, promoting the activation of self-reactive T cells. Accordingly, it is important to understand the contribution of these cells to the pathogenesis of SLE and the mechanisms responsible for their altered functionality during disease. One of the key enzymes that control monocyte and DC function is haem oxygenase-1 (HO-1), which catalyses the degradation of the haem group into biliverdin, carbon monoxide and free iron. These products possess immunosuppressive and anti-inflammatory capacities. The main goal of this work was to determine HO-1 expression in monocytes and DCs from patients with SLE and healthy controls. Hence, peripheral blood mononuclear cells were obtained from 43 patients with SLE and 30 healthy controls. CD14(+) monocytes and CD4(+) T cells were sorted by FACS and HO-1 expression was measured by RT-PCR. In addition, HO-1 protein expression was determined by FACS. HO-1 levels in monocytes were significantly reduced in patients with SLE compared with healthy controls. These results were confirmed by flow cytometry. No differences were observed in other cell types, such as DCs or CD4(+) T cells, although decreased MHC-II levels were observed in DCs from patients with SLE. In conclusion, we found a significant decrease in HO-1 expression, specifically in monocytes from patients with SLE, suggesting that an imbalance of monocyte function could be partly the result of a decrease in HO-1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.